BioPharmSignal logoBioPharmSignal

Biotech News

Teva to Host R&D Day on Wednesday, November 11 in New York City

Teva Pharmaceutical Industries (TEVA)Teva Pharmaceutical IndustriesCompany update

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva’s ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.

Related news

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva Releases Q3 2026 Aide Memoire

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

ARGXArgenx2026-09-29 12:00 EST

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

View all latest news

Teva Pharmaceutical Industries

Global Branded and Generic Medicines Company Teva Pharmaceutical Industries is a global pharmaceutical company with businesses in innovative medicines, generic drugs, biosimilars, and active pharmaceutical ingredients. Its commercial reach spans North America, Europe, and international markets, supported by large-scale manufacturing and...

Recent company news

TEVATeva Pharmaceutical Industries2026-10-12 21:45 EST

Teva to Host R&D Day on Wednesday, November 11 in New York City

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

TEVATeva Pharmaceutical Industries2026-09-30 20:32 EST

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Stock data

Close
40.62 USD
Market cap
38.52B USD
Exchange
NYSE
Sector
Biopharma
Location
United States